Medroxyprogesterone acetate (MPA) has no estrogenic activity, androgenic activity of its minimum. In small doses, it suppresses gonadotropin secretion of pituitary hormones (especially luteinizing hormone), resulting deca durabolin reviews in women of childbearing age prevents follicular maturation and observed prolonged anovulation.Reduces vasomotor symptoms in menopause, inhibits secretory changes in the endometrium, increases the viscosity of cervical mucus. When administered parenterally in high doses has antitumor effect in hormone-dependent malignancies. The antitumor effect is due, presumably, the influence on the hypothalamic-pituitary-gonadal system progestin and estrogen receptors, steroid metabolism at the cellular level. At high doses (500 mg / day or more) can manifest glucocorticoid activity.
After intramuscular administration of slow absorption that provides a low but constant concentrations of medroxyprogesterone in the blood plasma. Relationship to plasma proteins – 90-95%. It penetrates through the blood-brain barrier, excreted in breast milk. It is metabolized in the liver. The half – 6 weeks. Excreted in the bile, and the kidneys as metabolites and unchanged.
additional and palliative treatment of recurrent and metastatic endometrial cancer, kidney cancer; palliative treatment of hormone-dependent forms of breast cancer in women of recurrent cancer in postmenopausal women.
- hypersensitivity to medroxyprogesterone or any other substance included in the composition of the drug;
- vaginal bleeding of unknown etiology;
- expressed human liver;
- Pregnancy and lactation;Precautions:
thrombophlebitis, thromboembolism or stroke (increased risk of developing, or in history),
renal, hepatic or cardiac insufficiency,
hypercalcemia, epilepsy, migraine, asthma, diabetes, depression.
Dosing and dose
Medroxyprogesterone dose-LENS ® is determined individually and depends on the evidence. If endometrial cancer and kidney cancer: initial dose of 500 mg – 1000 mg 1 time per week. If in a few weeks or months in the patient’s condition began to improve and reached the stabilization process, the prescribed maintenance therapy at a dose of 500 mg per month. In breast cancer: an initial dose – 500 mg / day for 28 days. Then, maintenance doses are used – 500 mg 2 times a week. Treatment is continued until until there is a positive effect of the drug. The results of treatment of breast cancer can occur delayed -. Even after 8-10 weeks of initiation of treatment Immediately before use vial should be shaken well to the medication injected acquired form of uniform slurry.
Side Effects With the genitourinary system: dysfunctional uterine bleeding (irregular, copious, scanty), amenorrhea, changes in cervical secretions, cervical erosion, prolonged anovulation, libido changes.From the nervous system: confusion, depression, dizziness, euphoria, fatigue , headache, insomnia, decreased ability to concentrate, increased nervous irritability, drowsiness, visual disturbances. on the part of the digestive system: constipation, diarrhea, dry mouth, abnormal liver function, jaundice, nausea, vomiting, changes in appetite part of the endocrine system : galactorrhea, mammalgia, breast, or breast, the effects inherent corticosteroids (such as Cushing’s syndrome), impaired glucose tolerance, diabetic cataract, exacerbation of diabetes mellitus, glycosuria. cardio-vascular system: stroke, myocardial infarction, chronic heart failure, high blood pressure, feeling of palpitations, pulmonary embolism, thrombosis of the retinal vessels, tachycardia, thromboembolic disorders, thrombophlebitis. From hemopoiesis system: an increase in the number of white blood cells and platelets in the blood. With the skin side and skin appendages: acne, alopecia, hirsutism , pruritus, rash, urticaria. Immune System: hypersensitivity reactions (anaphylaxis and anaphylactoid reactions, angioedema). Local reactions: pain, residual seals, discoloration of the skin at the injection site. Other: edema / fluid retention, hypercalcemia, pyrexia, weight change, adrenergic effects (such as tremor, sweating, leg cramps at night), a decrease in bone density (FCT).
application deca durabolin reviews is very high doses may cause a variety of symptoms including weight gain (with some fluid retention), fatigue, and in some cases effects inherent corticosteroids. In cases of overdose should stop using the product. No specific treatment is required.
The interaction with other drugs
Aminoglutethimide reduces the plasma concentration of medroxyprogesterone acetate, which may lead to a decrease in its effectiveness.
The drug is used strictly for its intended purpose and under medical supervision. In dysfunctional uterine bleeding should be excluded uterine cancer and others. Organic lesions.
In the treatment of patients, the condition of which may adversely affect the fluid retention in the body need to be careful.
When drug therapy is necessary to closely monitor the condition of patients who have previously been treated for depression.
When treating diabetes patients should take into account the ability of the IPA to reduce glucose tolerance.
If on a background of drug treatment is carried out cytological and histological examination of the endometrium or cervix, must notify pathologist for therapy.
with the sudden partial or complete loss of vision, or the sudden development of exophthalmos, double in the eyes, migraine attacks should immediately stop taking the drug. In identifying vascular damage tissue or nipple swelling of the optic nerve treatment IPA should be canceled.
Despite the fact that the causal relationship between the use of IPA and the development of thromboembolic disorders have been identified in patients with these disorders in history or in the event of them during treatment should be carefully evaluated possible risks and benefits of the appointment, or deciding whether to continue treatment. Use of IPA as contraceptive intramuscularly with 150 mg of 1 every 3 months in adult women of childbearing age and adolescents reduces loin bones PKT 5 years on average 5.4% and 4.2%, respectively, while during the first 2 years after the drug is partially restored bone.The largest decrease of PCT observed in the first 2 years of the drug. All patients applying IPA, it is recommended to take calcium supplements and vitamin D, and in some cases, long-term use -. Periodically measure the PBC
in some patients taking MPA revealed suppression of adrenocortical function (reduction of the concentration of adrenocorticotropic hormone (ACTH) in the blood of hydrocortisone .)
in laboratory studies should take into account that the use of MPA may decrease the levels of the following endocrine biomarkers: plasma and urinary steroids (cortisol, estrogen, pregnandiol, progesterone, testosterone); gonadotropins deca durabolin reviews in plasma and in urine (LH and FSH); specific binding globulin sex hormones.
In conducting metapironovogo test should take into account that high doses of MPA used in oncology, can cause partial adrenal insufficiency (decrease in the response of the pituitary-adrenal axis), so that before the introduction of metapyron necessary to test the ability of adrenal cortex to respond to ACTH.